We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Semaglutide successfully treats liver illness in two thirds of sufferers, analysis finds
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Semaglutide successfully treats liver illness in two thirds of sufferers, analysis finds
Semaglutide successfully treats liver illness in two thirds of sufferers, analysis finds
Health

Semaglutide successfully treats liver illness in two thirds of sufferers, analysis finds

Last updated: May 1, 2025 1:47 am
Editorial Board Published May 1, 2025
Share
SHARE

Credit score: Unsplash/CC0 Public Area

Outcomes from the ESSENCE Part III medical trial printed within the New England Journal of Medication present treating sufferers with semaglutide can halt and even reverse liver illness.

The placebo-controlled consequence trial of members with a life-threatening type of liver illness often known as metabolic dysfunction related steatohepatitis (MASH) was performed at 253 medical websites throughout 37 international locations all over the world. That is the primary regulatory-level trial displaying the advantage of semaglutide for folks with MASH.

Metabolic dysfunction-associated steatotic liver illness (MASLD), previously often known as non-alcoholic fatty liver illness (NAFLD), is a long-lasting liver situation brought on by having an excessive amount of fats within the liver. MASH is a extra extreme type of MASLD. It’s carefully linked with weight problems in addition to circumstances corresponding to sort 2 diabetes and coronary heart and circulatory illness.

Over time, the build-up of fats within the liver can result in irritation, liver fibrosis, cirrhosis and liver most cancers. MASLD impacts one in 5 folks within the UK however there are not any medicines licensed to particularly deal with the illness.

Between Might 27, 2021 and April 18, 2023, 800 members have been randomly assigned to obtain a once-weekly injection of two.4 milligrams of semaglutide or placebo, alongside life-style counseling. Greater than half of the members had sort 2 diabetes and roughly three-quarters have been residing with weight problems.

Outcomes from the ESSENCE trials after 72 weeks of remedy discovered 62.9% of members skilled a discount in steatohepatitis (irritation of the liver with fats accumulation within the liver) versus 34.3% for members who took the placebo. The outcomes additionally present 36.8% of the semaglutide group had enhancements of their liver fibrosis versus 22.4% within the placebo group.

Researchers additionally discovered different advantages. These receiving semaglutide additionally noticed enhancements in liver enzymes and different blood measures of liver fibrosis, in addition to 10.5% weight reduction. Gastrointestinal adversarial occasions have been extra frequent within the semaglutide group, corresponding to nausea, diarrhea, constipation, and vomiting.

The analysis staff will use near 1,200 members from 37 international locations for as much as 5 years to collect information on semaglutide’s affect on long-term liver problems.

Extra data:
Part 3 Trial of Semaglutide in Metabolic Dysfunction-Related Steatohepatitis, New England Journal of Medication (2025).

Offered by
King’s Faculty London

Quotation:
Semaglutide successfully treats liver illness in two thirds of sufferers, analysis finds (2025, April 30)
retrieved 30 April 2025
from https://medicalxpress.com/information/2025-04-semaglutide-effectively-liver-disease-thirds.html

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.

You Might Also Like

What a illness in cats might train us about lengthy COVID

Research finds shorter remedy efficient for some with drug-resistant tuberculosis

Aluminum publicity from childhood vaccines not linked to elevated threat of sure continual issues

Anti-obesity medicines can normalize testosterone ranges in males

New wearable system provides steady, noninvasive hydration monitoring for day by day use

TAGGED:diseaseeffectivelyfindsLiverpatientsResearchSemaglutidethirdstreats
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Live Updates: As Ukraine Resists Russian Advance, World Rallies in Support
World

Live Updates: As Ukraine Resists Russian Advance, World Rallies in Support

Editorial Board February 27, 2022
Making ‘Dinobabies’ Extinct: IBM’s Push for a Younger Work Force
New immune increase might develop entry to most cancers immunotherapy
Harris Emerges as the Voice of Abortion Rights in the Biden Administration
Warmth dome to carry record-breaking temps to NYC, a lot of Northeast

You Might Also Like

Donor-egg pregnancies could include greater charges of great problems. Here is what it’s essential to know
Health

Donor-egg pregnancies could include greater charges of great problems. Here is what it’s essential to know

July 14, 2025
New immunology-driven radiation remedy methods showcased at convention
Health

New immunology-driven radiation remedy methods showcased at convention

July 14, 2025
Endocrine Society guideline requires elevated screening for frequent explanation for hypertension
Health

Endocrine Society guideline requires elevated screening for frequent explanation for hypertension

July 14, 2025
Novel open-source diagnostic software presents inexpensive, dependable pathogen detection for resource-limited settings
Health

Novel open-source diagnostic software presents inexpensive, dependable pathogen detection for resource-limited settings

July 14, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?